Hello, everyone, and welcome to the middle of the week. You made it this far, so why not continue, yes? Besides, consider the alternatives. While you ponder the possibilities, perhaps a cup or two of stimulation is in order. As you know, a prescription is not required. So feel free to indulge as you attack the laundry list of meetings and deadlines that await. Meanwhile, we have once again assembled a list of tidbits for you to peruse and help you on your way. Hope you have a smashing day and, as always, do drop us a line when you hear something interesting.

The White House signaled President Donald Trump’s blunt thumbs-down to House Speaker Nancy Pelosi’s plan allowing Medicare to negotiate drug prices, the Associated Press reports. Although lowering drug prices is a mutual objective and a top concern for Americans across party lines, a senior White House official says the Pelosi plan is “unworkable” and Trump will instead support bipartisan legislation pending in the Senate. The falling-out imperils chances for legislation this year, already seen as a long shot.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy